Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Observer-Blind, Multi-Center Study to Evaluate the Safety, Potential Efficacy, and Pharmacokinetics of Two Dosing Regimens of Intravenous PZ-601 and Standard of Care in the Treatment of Complicated Skin and Skin Structure Infections

NCT00671580 is registered in ClinicalTrials.gov with Protez Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00671580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00671580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Observer-Blind, Multi-Center Study to Evaluate the Safety, Potential Efficacy, and Pharmacokinetics of Two Dosing Regimens of Intravenous PZ-601 and Standard of Care in the Treatment of Complicated Skin and Skin Structure Infections
Lead sponsor
Protez Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2008
Completion date
February 28, 2009
Enrollment
99 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

skin infections